Do Institutional Investors Love Integrated Biopharma Inc (NYSE:INB)?

January 9, 2018 - By Louis Casey

 Do Institutional Investors Love Integrated Biopharma Inc (NYSE:INB)?

Sentiment for Integrated Biopharma Inc (NYSE:INB)

Integrated Biopharma Inc (NYSE:INB) institutional sentiment increased to 1.46 in 2017 Q3. Its up 0.13, from 1.33 in 2017Q2. The ratio increased, as 19 institutional investors opened new and increased stock positions, while 13 sold and decreased their equity positions in Integrated Biopharma Inc. The institutional investors in our partner’s database reported: 2.76 million shares, up from 2.76 million shares in 2017Q2. Also, the number of institutional investors holding Integrated Biopharma Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 7 Reduced: 6 Increased: 8 New Position: 11.

The stock decreased 0.68% or $0.07 during the last trading session, reaching $10.25. About 75,889 shares traded. Cohen & Steers Global Income Builder, Inc (NYSE:INB) has risen 7.96% since January 9, 2017 and is uptrending. It has underperformed by 8.74% the S&P500.

Shaker Financial Services Llc holds 1.21% of its portfolio in Cohen & Steers Global Income Builder, Inc for 234,987 shares. Cutter & Co Brokerage Inc. owns 58,670 shares or 0.23% of their US portfolio. Moreover, Cornerstone Advisors Inc has 0.05% invested in the company for 40,680 shares. The Alabama-based Kistler has invested 0.03% in the stock. Allsquare Wealth Management Llc, a New York-based fund reported 2,000 shares.#img1#

More news for Cohen & Steers Global Income Builder, Inc (NYSE:INB) were recently published by:, which released: “Cohen & Steers Global Income Builder, Inc. (INB) Ex-Dividend Date Scheduled …” on September 19, 2016.‘s article titled: “Cohen & Steers Closed-End Funds Declare Distributions for October, November …” and published on September 28, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.